Jardiance Tablet, Film Coated
Product Images NDC 50090-4384
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Jardiance (NDC 50090-4384). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Jardiance 02
This is a list of medications with their doses and frequencies. These include antidiabetic drugs such as metformin, gimepiride, pioglitazone, shagliptin, and linagliptin. Other drugs listed include simvastatin, werferin, verapamil, ramipril, gemfibrozi, hydrochlorothiazide, torsemide, rifampicin, and probenecid. The table also shows the geometric mean ratio and change relative to empagliflozin alone.*
Jardiance 03
Jardiance 04
The text is describing the mean change from baseline HbA1C (%) for a placebo group and two Empagliflozin groups (one taking 10mg and the other 25mg). The change is measured at various time intervals up to 24 weeks. The data has been adjusted for baseline HbA1C, geographical region, and oGFR at baseline.*
Jardiance 05
Jardiance 06
This appears to be a table of data related to patients and their treatments with a medication called Empaglifiozin. The table shows the number of patients who experienced an "event" and the total number of subjects at risk for each treatment group (Placebo vs. Empaglifiozin). However, without additional context, it is difficult to determine the specifics of the "event" or the purpose of the study.*
Jardiance 07
Jardiance 08
Jardiance 08a
Jardiance 08b
Jardiance 08c
This appears to be a table containing details related to a study. It seems to include various subgroups and categories along with the number of males and females. Additionally, there is information on age, race, heart failure physiology, baseline use of medications, and the number of individuals with events and analyzed. The table also includes a hazard ratio and interaction value. A conclusion can be drawn from this information on whether Empagifiozin 10mg was better or Placebo was better, but without further context, it is difficult to understand the study completely.*
Label Image (Lbl500904384)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.